SCHEMBL16857041

SCHEMBL16857041

COC(=O)c1ccc(O[Si](C)(C)C(C)(C)C)cc1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 5/20 0.53
GAA P10253 4/20 0.53
HSD17B10 Q99714 3/20 0.53
GLA P06280 2/20 0.53
MAPT P10636 2/20 0.53
HPGD P15428 2/20 0.53
CASP1 P29466 1/20 0.53
CASP7 P55210 1/20 0.53
ATM Q13315 1/20 0.53
CFTR P13569 6/20 0.51
ABL1 P00519 1/20 0.51
CA12 O43570 4/20 0.43
CA1 P00915 4/20 0.43
CA9 Q16790 4/20 0.43
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6519025 0.89 KDM4E (0.50) ALDH1A1KDM4EGAAHSD17B10GLA
SCHEMBL20046200 0.84 CA1 (0.43) ALDH1A1KDM4EGAAHSD17B10GLA
SCHEMBL7628586 0.81 CA12 (0.53) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL2201771 0.81 CA12 (0.43) KDM4EGAAMAPTCA12CA1
SCHEMBL30007012 0.81 CA12 (0.43) KDM4EGAAMAPTCA12CA1
SCHEMBL25370505 0.81 CA12 (0.41) ALDH1A1KDM4EGAAHSD17B10GLA
SCHEMBL20231316 0.81 CA12 (0.41) ALDH1A1KDM4EGAAHSD17B10GLA
SCHEMBL29614665 0.81 CA12 (0.41) ALDH1A1KDM4EGAAHSD17B10GLA
SCHEMBL7627705 0.80 MAPT (0.44) ALDH1A1KDM4EGAAHSD17B10GLA
SCHEMBL6955161 0.78 GAA (0.39) ALDH1A1KDM4EGAAHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150299188-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-10-22 US disclosed
EP-2889291-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-07-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299188-A1 HETEROCYCLIC COMPOUND PTGIS, LIPG, FEN1 ALDH1A1 640/4885KDM4E 2873/4885GAA 861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.